phenprocoumon - Profile

What are the generic sources for phenprocoumon and what is the scope of freedom to operate?

Phenprocoumon is the generic ingredient in one branded drug marketed by Organon Usa Inc and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Summary for phenprocoumon

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for phenprocoumon

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Organon Usa Inc	LIQUAMAR	phenprocoumon	TABLET;ORAL	011228-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Summary

Last updated: February 3, 2026

Phenprocoumon, an oral anticoagulant primarily used for thromboembolic prophylaxis, represents a niche yet significant segment within the anticoagulant market. Its unique pharmacokinetic profile—long half-life and selective anticoagulant action—distinguishes it from direct oral anticoagulants (DOACs) like dabigatran and rivaroxaban. Despite its established presence in European markets, phenprocoumon faces increasing competition driven by evolving regulatory landscapes, technological advancements, and shifting clinical guidelines favoring DOACs. This report examines market dynamics, investment opportunities, and future financial trajectories associated with phenprocoumon, emphasizing factors influencing its commercialization, patent landscape, and competitive positioning.

1. Market Overview: Phenprocoumon in the Global Anticoagulant Market

1.1. Product Profile and Pharmacokinetics

Characteristic	Phenprocoumon
Therapeutic Class	Vitamin K antagonist (VKA)
Half-life	5-7 days
Onset of action	2-4 days
Reversal Agent	Vitamin K, prothrombin complex concentrate (PCC)
Indications	Atrial fibrillation, deep vein thrombosis, pulmonary embolism

Pharmacokinetic advantage: Longer half-life reduces dosing frequency versus warfarin, but impairs rapid reversal during bleeding events or urgent surgeries.

1.2. Market Penetration and Regional Dynamics

• Europe: Dominant market, with phenprocoumon approved and predominantly prescribed in countries like Germany, Austria, and Switzerland.
• United States: Absent from the market; warfarin remains the main VKA, with DOACs taking precedence.

1.3. Key Players and Manufacturers

Company	Product Name	Market Share (Europe)	Notes
Boehringer Ingelheim	Marcoumar (phenprocoumon)	~60%	Leading formulation, patent status varies
Other Manufacturers	Market fragmented	N/A	Limited, regional competition

2. Investment Scenario

2.1. Rationale for Investment

• Established Market: Phenprocoumon benefits from continued use in countries with conservative anticoagulation protocols.
• Patent Landscape: Off-patent, facilitating generics and reducing R&D costs; however, patent expirations for formulations are nearing, opening avenues for new entrants.
• Growing but Aging Incumbent Base: Population aging drives demand, but the shift toward DOACs reduces new prescriptions for VKAs.

2.2. Opportunities and Risks

Opportunities	Risks
Leverage regional presence in Europe	Competition from DOACs and emerging anticoagulants
Formulation innovations (e.g., alternative delivery)	Declining share due to guideline shifts
Strategic partnerships with regional distributors	Regulatory hurdles for new formulations

2.3. Investment Models

Model	Pros	Cons
Licensing & Partnerships	Lower capital expenditure; faster market access	Limited control over commercialization
In-house Development	Innovation potential, branding control	High R&D investments; regulatory complexity
Generic Manufacturing	Cost-effective; high volume	Price competition; eroded margins

3. Market Dynamics and Drivers

3.1. Regulatory Policies

• European Medicines Agency (EMA): Supports continued use of VKAs where DOACs are contraindicated or unavailable (e.g., certain renal impairments).
• FDA: No phenprocoumon approval; U.S. market only features warfarin and DOACs.

3.2. Technological and Clinical Trends

• Shift Toward DOACs: Easier dosing and no requirement for regular INR monitoring have shifted prescriptions (e.g., Xarelto, Eliquis).
• Regulatory Incentives: Potential for label extensions or new formulations via orphan drug pathways or patent extensions.

3.3. Competitive Landscape

Competitors	Key Differentiators	Market Status
Warfarin (various brands)	Established, low-cost, widely known	Mature, declining in use
DOACs (e.g., dabigatran, rivaroxaban)	Fixed dosing, no INR monitoring needed	Accelerating adoption
Emerging anticoagulants	New mechanisms, targeted therapies	Early-stage development

3.4. Price and Reimbursement

• Europe: Reimbursement largely favors generics; pricing pressure is intense.
• Pharmacoeconomic evaluations: Favor DOACs in high-risk populations due to reduced monitoring costs, pressuring phenprocoumon's market share.

4. Financial Trajectory and Projection

4.1. Market Size and Growth Estimates (2023-2030)

Parameter	Estimate	Source/Assumption
Current European phenprocoumon market value	USD 500 million	Based on regional sales figures
CAGR (2023–2030)	-2% to -4%	Decline due to DOAC uptake
Total regional VKA market (including warfarin)	USD 1.2 billion	Market reports (e.g., IQVIA)
Potential niche growth in underserved regions	Moderate (3-5%) in select markets	Emerging markets, limited competition

4.2. Revenue Projection Scenarios

Scenario	Assumptions	Estimated Revenue (USD, 2030)
Conservative (status quo)	Decline continues at 3% annually	USD 300 million
Moderate growth	Slight market share stabilization, innovation	USD 400 million
Aggressive diversification	Entry into niche segments or new formulations	USD 500 million

4.3. Cost Factors

• Manufacturing: Low to moderate, depending on scale and capacity.
• Regulatory costs: Moderate, especially for new formulations or indications.
• Marketing & distribution: Significant in competitive markets.

5. Comparison with Alternatives

Aspect	Phenprocoumon	Warfarin	DOACs
Dosing Convenience	Long half-life, less frequent	Daily, requires frequent INR monitoring	Fixed, once or twice daily
Reversal Procedure	Vitamin K, PCC (less rapid)	Vitamin K, PCC	Specific reversal agents (e.g., idarucizumab, andexanet alfa)
Market Acceptance	Regional, limited US	Global, well-established	Growing rapidly
Cost	Moderate (generic)	Low	High

6. Regulatory and Patent Outlook

Aspect	Status	Implication
Patent expiration (original formulations)	Approaching (mid-2020s)	Increased generic competition
New formulation approval	Potential for innovative delivery or indications	Market differentiation possible
Regulatory barriers	Moderate; jurisdiction-specific	May delay new product launches

7. FAQs

Q1: Is phenprocoumon a viable long-term investment given the global move toward DOACs?
A1: Its viability hinges on regional market stability, especially in Europe, where established use persists. Niche markets or formulations can sustain profitability; however, global expansion remains limited without strategic innovation.

Q2: What regulatory challenges exist for phenprocoumon?
A2: Mainly related to patent expirations, formulation approval, and compliance with EU standards. U.S. markets are inaccessible due to lack of FDA approval.

Q3: How do generic options affect the profitability of phenprocoumon?
A3: Generics drive down prices, pressuring margins but increase volume potential. Market entry strategies could involve differentiated formulations or targeted indications.

Q4: What factors might reverse the declining trend of phenprocoumon usage?
A4: Development of new formulations, expanded indications, or significant clinical evidence favoring VKAs in specific populations could sustain or boost demand.

Q5: How does the competitive landscape affect investment in phenprocoumon?
A5: Intense competition from DOACs leads to market share erosion but also opens opportunities for niche development, rapid regulatory approval of modified formulations, or regional dominance.

Key Takeaways

• Phenprocoumon retains a regional stronghold in Europe, especially where clinical inertia favors VKAs.
• The market faces decline at -2% to -4% annually, driven by DOAC adoption and formulary shifts.
• Opportunities exist in niche markets, formulation innovation, and regional regulatory incentives.
• Post-patent expiration, cost competitiveness benefits generic manufacturers but diminishes profitability.
• Strategic focus should be on differentiation, partnerships, and expanding indications to sustain long-term viability.

References

[1] IQVIA. "Global Anticoagulant Market Report," 2022.
[2] European Medicines Agency. "Guidelines on anticoagulant use," 2021.
[3] MarketsandMarkets. "Oral Anticoagulants Market Share Analysis," 2022.
[4] Boehringer Ingelheim. "Marcoumar product information," 2022.
[5] ClinicalTrials.gov. "Research and development trends in VKAs," 2023.